once-daily in combination with an optimized background therapy in adult
treatment-experienced HIV patients with R5-type virus only. (Announced
Sept. 17)
-- Reported that the Committee for Medicinal Products for Human Use (CHMP)
of the European Medicines Agency (EMEA) had issued a positive opinion
recommending approval of combination therapy with PEGINTRON
(peginterferon alfa-2b) and REBETOL (ribavirin) for retreating adult
patients with chronic hepatitis C whose previous treatment with
interferon alpha (pegylated or non-pegylated) and ribavirin combination
therapy or interferon alpha monotherapy did not result in a sustained
response. (Announced Sept. 24)
-- Received approval from the European Commission for Schering-Plough's
planned acquisition of Organon BioSciences N.V. from Akzo Nobel N.V.
(Announced Oct. 11)
-- Provided an update on the clinical development program for boceprevir,
the company's investigational oral hepatitis C protease inhibitor. In
a Phase II study in treatment-nave hepatitis C patients, boceprevir
combination therapy with PEGINTRON and REBETOL achieved a high rate of
early virologic response. In a second study in treatment non
responders (the most difficult-to-treat patient population), while
boceprevir combination therapy with PEGINTRON and REBETOL demonstrated
antiviral activity, the majority of patients did not achieve a
sustained virologic response (SVR). No increase in skin adverse events
(rash) beyond what was seen in the control group was observed in these
studies. (Announced Oct. 18)
Third Quarter 2007 Conference Call and Webcast
Schering-Plough will conduct a conference call today at 8 a.m. (EDT) to
review the 2007 third quarter results. To listen live to the call, di
'/>"/>
| SOURCE Schering-Plough Corporation Copyright©2007 PR Newswire. All rights reserved |